Chest, Vol 93, 1126-1131, Copyright © 1988 by American College of Chest Physicians

ARTICLES

Gallium lung scintigraphy in amiodarone pulmonary toxicity

YY Zhu, E Botvinick, M Dae, J Golden, R Hattner and M Scheinman
Department of Radiology, University of California, San Francisco.

We sought to assess the role of gallium-67 lung scintigrams in the evaluation of amiodarone pulmonary toxicity. Images and laboratory studies were evaluated in 54 patients who had chest radiographs and scintigraphic studies during amiodarone treatment of more than one month's duration among 561 patients receiving the medication for refractory arrhythmias. There were 22 patients with pulmonary symptoms and clinical evidence of amiodarone pulmonary toxicity (group 1); 19 patients had other causes for pulmonary symptoms (group 2); and 21 patients were without symptoms or other clinical evidence of pulmonary toxicity (group 3). There was no difference among groups in treatment duration or total amiodarone dose. Symptomatic presentation could not differentiate between group 1 and group 2 patients. However, radiographic findings of isolated pulmonary congestion or a normal radiograph in the presence of symptoms made amiodarone toxicity unlikely, while the appearance of new, dense radiographic infiltrates-- often in a nodular distribution--were more frequent among group 1 patients (p less than 0.01). During symptomatic periods, 18 of 22 group 1 patients had abnormal gallium lung uptake, while four revealed more subtle serial changes but there was only one abnormal scintigram among symptomatic group 2 patients. Nonspecific radiographic abnormalities in patients with pulmonary symptoms on amiodarone therapy were rarely attributed to toxicity in the presence of a normal scintigram. One group 3 patient developed scintigraphic abnormalities early during amiodarone treatment, suggesting toxicity in the presence of a normal chest x-ray examination. Comparison of radiographic and scintigraphic studies performed during symptoms with those performed prior to symptom development best indicated the diagnosis, while comparison with later images assessed the efficacy of treatment. Diffusion capacity testing and transbronchial biopsy were sensitive but not specific for the diagnosis of amiodarone toxicity. Gallium image abnormalities parallel the development of amiodarone pulmonary toxicity and aid this diagnosis, especially when the chest radiograph is abnormal and ambiguous. Serial increments in scintigraphic abnormality appear especially helpful for diagnosis in the population at risk.